Posted by Michael Wonder on 16 Jan 2025
Foresee Pharmaceuticals announces the PDUFA goal date for the 3 month version of Camcevi is 29 August 2025
13 January 2025 - Foresee Pharmaceuticals announces that the US FDA issued a Day 74 letter.
The Day 74 letter states that the PDUFA goal date for a decision on marketing approval for the 3 month version of Camcevi (leuprolide mesylate 21 mg, 3 month long-acting injectable formulation) for the treatment of adult patients with advanced prostate cancer is 29 August 2025.
